ONCT - Oncternal Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.48
+0.04 (+0.74%)
As of 12:45PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close5.54
Open5.70
Bid5.41 x 800
Ask5.55 x 1400
Day's Range5.48 - 5.70
52 Week Range3.43 - 17.92
Volume1,737
Avg. Volume26,150
Market Cap84.309M
Beta (3Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-1.81
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • Business Wire

    Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma

    Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has opened for enrollment a Phase 1b expansion cohort of its Phase 1/2 clinical trial of cirmtuzumab, a ROR1-targeted monoclonal antibody, combined with ibrutinib, in patients with mantle cell lymphoma (MCL). The decision to open an expansion cohort in MCL of the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial was based on favorable interim results from the dose-finding cohort of the trial, including that the combination was well-tolerated and that complete responses were observed in two heavily pre-treated patients who had received and failed multiple chemotherapy regimens and an autologous transplant, as well as either an allotransplant or CAR-T therapy, prior to participating in this clinical trial.

  • We're Not Very Worried About Oncternal Therapeutics's (NASDAQ:ONCT) Cash Burn Rate
    Simply Wall St.

    We're Not Very Worried About Oncternal Therapeutics's (NASDAQ:ONCT) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • Business Wire

    Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Children’s Oncology Group Meeting

    Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that Paul A. Meyers, M.D., Chief, Pediatric Sarcoma Service and Vice Chair for Clinical Affairs of Memorial Sloan Kettering Cancer Center, presented a case study of a patient with Ewing sarcoma who achieved a sustained response following treatment with Oncternal’s investigational product candidate, TK216, in an ongoing Phase 1, first-in-human clinical trial. The presentation entitled, “TK216 for the Treatment of Ewing Sarcoma,” was given at the Fall Children’s Oncology Group (COG) Meeting.

  • Business Wire

    Oncternal Further Expands Executive Team; Appoints Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer

    Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical needs, today announced the appointment of Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer. “Dr. Kaufmann brings to Oncternal significant expertise in advancing preclinical programs from concept to the clinic and successfully initiating and executing collaborations with corporate partners, and Dr. Bilinsky has extensive experience in business strategy, corporate development and strategic partnering,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO.

  • GlobeNewswire

    Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update

    SAN DIEGO, Aug. 08, 2019 -- Interim objective response rate of 100% in evaluable patients with CLL receiving the recommended dosing regimen of cirmtuzumab + ibrutinib supports.

  • GlobeNewswire

    Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib

    Oncternal Therapeutics, Inc., (Nasdaq: ONCT) a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical need, today announced that it has opened for enrollment its randomized Phase 2 study of cirmtuzumab, a ROR1-targeted monoclonal antibody, combined with ibrutinib in patients with chronic lymphocytic leukemia (CLL). The decision to open Phase 2 of the company’s ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial was triggered by favorable outcomes from the Part 1 dose-finding and Part 2 dose-confirming cohorts of the clinical trial, including an observed interim objective response rate (ORR) of 100% for the first 9 CLL patients with evaluable data receiving the recommended dosing regimen who have completed 12 weeks of cirmtuzumab plus ibrutinib treatment in Part 2, and a well-tolerated safety profile consistent with that seen with ibrutinib treatment alone.

  • GlobeNewswire

    Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update

    Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical need, today announced that it will report second quarter 2019 financial results after the market closes on Thursday, August 8, 2019. Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing a diverse pipeline of product candidates for the treatment of cancers with critical unmet medical need. Oncternal’s pipeline includes its lead clinical program, cirmtuzumab, a monoclonal antibody designed to inhibit the ROR1 receptor that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma, and TK-216, a small-molecule compound that is designed to inhibit ETS-family oncoproteins, which is being evaluated in a Phase 1 clinical trial alone and in combination with vincristine as a treatment for Ewing sarcoma, a rare pediatric cancer.

  • GlobeNewswire

    Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.

    Oncternal Therapeutics, Inc., (Nasdaq: ONCT) a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical need, today announced that the reverse merger with GTx, Inc., closed on June 7, 2019. “We believe that the closing of the merger signifies a transformative event that will provide Oncternal with the opportunity to achieve its next level of corporate growth as we continue to advance our promising oncology drug candidates through development,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO.